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Background: The four-herb Chinese medicine PHY906(KD018) has been shown to both enhance the in vivo antitumor
activity of irinotecan (CPT-11) against colon cancer tumor allografts and alleviate intestinal toxicity caused by CPT-11.
Methods: Since intestinal bacteria can metabolize CPT-11 and PHY906, we investigated whether intestinal bacteria play
a critical role in the in vivo activity of PHY906 in murine Colon-38 tumor-bearing mice. Intestinal bacteria were depleted
using streptomycin/neomycin for 10 days before and during treatment with PHY906 and/or CPT-11. qPCR using 16S
DNA group-specific primers was used to quantify the levels of the major intestinal bacteria.
Results: Both PHY906 and antibiotic treatment changed the profile of intestinal bacteria species: Lactobacillus/
Enterococcus, Bacteroides, Clostridium leptum, and E. rectale/C. coccoides. Antibiotic treatment did not alter the
ability of PHY906 to enhance the antitumor activity of CPT-11. Antibiotic treatment alone partially reduced animal
body weight loss in CPT-11-treated mice. However, PHY906 treatment was able to protect against the body weight
loss in the CPT-11/antibiotic treatment group. H&E and PCNA staining of intestine showed that antibiotic treatment
partially reduced the intestinal damage caused by CPT-11 but not as effectively as PHY906 treatment. Antibiotic
treatment plus PHY906 conferred the most effective protection of intestine histological structure against damage
by CPT-11. Both PHY906 and antibiotic treatment inhibited CPT-11-associated inflammatory processes, including
infiltration of the intestine by neutrophils, MCP1 and TNF-alpha mRNA expression in the intestine, and expression
of pro-inflammatory cytokines G-CSF and MCP1 proteins in the plasma. However, whereas antibiotic treatment
suppressed the mRNA expression of two important intestinal progenitor/stem cell markers, Olfm4 and Lgr5,
PHY906 treatment resulted in enhanced expression of these two stem cell markers.
Conclusions: Alterations in the population of intestinal bacteria did not affect the abilities of PHY906 to enhance
CPT-11 antitumor activity or reduce the intestinal toxicity associated with CPT-11 treatment. The major
species of intestinal bacteria do not appear to play a role in PHY906’s enhancement of the therapeutic index of
CPT-11 in tumor-bearing mice. Thus, patients with different intestinal bacterial profiles may still benefit from PHY906
treatment alongside CPT-11.* Correspondence: ycccheng@yale.edu
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PHY906 (KD018) is based on the formulation Huang Qin
Tang (HQT), which consists of four main herbs: Glycyr-
rhiza uralensis Fisch (G), Paeonia lactiflora Pall (P), Scu-
tellaria baicalensis Georgi (S), and Ziziphus jujuba Mill
(Z). Huang Qin Tang has been used for over 1800 years
to treat a variety of gastrointestinal symptoms including
diarrhea, nausea and vomiting, and abdominal cramps.
PHY906 is manufactured using high-quality herbs picked
by experienced herbalists and manufactured following
cGMP (current Good Manufacturing Practice). Consistent
preparations of PHY906 have been made over a period of
10 years as documented by Phytomics QC using standard-
ized chemical and biological fingerprints [1].
Irinotecan (CPT-11) in combination with 5-fluorouracil
(5-FU) and leucovorin continues to be used as the first-
line therapy for treatment of metastatic colorectal cancer
(mCRC). CPT-11 is also approved as a second-line mono-
therapy for recurrent mCRC following treatment with
an oxaliplatin-based regimen. The dose-limiting toxic-
ities of CPT-11 include nausea and vomiting, abdominal
pain/cramps, and diarrhea. CPT-11 administration has
also been shown to cause gastrointestinal bleeding, a symp-
tom often associated with colonic ulceration resulting from
intestinal cell death and inflammation (3). Once CPT-11
is administrated, it is converted to the active metabolite
SN-38 (7-Ethyl-10-hydroxy-camptothecin) by hepatic
and intestinal carboxyesterases [2-4]. SN-38 damages
DNA in intestinal cells as well as tumor cells, and can
trigger acute life-threatening diarrhea in patients [5]. In
the liver, SN-38 is metabolized by hepatic UDP–glucur-
onyltransferase into the inactive SN-38G metabolite,
which is excreted into the jejunum via the bile duct [6,7].
Intestinal bacterial β-glucuronidase can convert SN-38G
back into the SN-38 metabolite, which can directly dam-
age the intestine and promote intestinal inflammation.
Several approaches have been used to reduce GI toxicity
resulting from CPT-11-based chemotherapy, including
modification of the schedule of administration [8,9], intes-
tinal alkalization [10,11], treatment with anti-diarrheal
therapies [12-16], genetic testing [17], ABCB1 transporter
inhibitor treatment [18,19], treatment with enzyme
(β-glucuronidase, UGT1A1, carboxylesterase, COX-2) in-
ducers or inhibitors [20-23], antibiotic treatment [24-26],
treatment with adsorbing agents [27,28], and treatment
with other agents [29-32]. However, to date, none of these
approaches has been found to be of significant clinical
benefit.
Since Huang Qin Tang has been used for over 1800
years ago to treat diarrhea, PHY906 was chosen as a po-
tential treatment strategy to reduce the GI side effects
associated with CPT-11 treatment. In in vivo pre-clinical
studies, PHY906 reduced the GI toxicities caused by CPT-
11 while simultaneously enhancing CPT-11’s in vivoantitumor activity [33]. Each of the four main herbs com-
prising the PHY906 formula was required to maximize
both its cytoprotective and antitumor effects. A phase 1/2
randomized double-blinded, placebo-controlled clinical
trial was conducted to examine PHY906’s clinical potential
as an adjuvant to CPT-11, 5-fluorouracil, and leucovorin
(5FU/LV) for the treatment of chemotherapy-naive mCRC
patients. PHY906 treatment resulted in a significant de-
crease in the incidence of nausea/vomiting and diarrhea,
and of note, treatment with PHY906 was not associated
with any toxicity on its own [34,35]. The pharmacokinet-
ics of CPT-11 and 5FU, respectively, was not affected by
PHY906 treatment [34].
PHY906 is orally administrated, and the individual
herbal components can be metabolized and transformed
by gut flora. Individuals may carry different profiles of in-
testinal bacteria in their GI system depending on gender
[36], diet [37], age [38], and co-morbid illnesses [38,39].
Therefore, the impact of PHY906 may be different for in-
dividuals with different spectra of intestinal flora. To test
this hypothesis, we investigated the potential interaction
of PHY906 and CPT-11 on intestinal damage and antitu-
mor activity in mice with or without depletion of intestinal
bacteria. Our findings demonstrate that the ability of
PHY906 to increase the therapeutic index of PHY906
is not affected by levels of major bacteria species in the
intestine.
Methods
Murine Colon-38 cells were transplanted subcutaneously
into four- to six-week-old female BDF1 mice (Charles
River Laboratories, Wilmington, MA). After 10 to 14 days,
mice with tumor sizes of 150–300 mm3 were selected. In-
testinal bacteria were depleted using streptomycin/neomy-
cin (200 mg/kg, p.o. bid) for 10 days before and during
the treatment of PHY906 and/or CPT-11. PHY906 was
given orally (p.o.) for four days (twice per day; b.i.d.,
500 mg/kg) and CPT-11 (360 mg/kg) was administered
intraperitioneally (i.p.) on day 0. On day 0, PHY906
was given 30 minutes prior to CPT-11 administration.
Mice (BDF1 bearing Colon-38 tumors) were terminated
by cervical dislocation on day 4. Total DNA of the middle
jejunum and the colon were purified using DNeasy Blood
& Tissue Kit (Qiagen, Germantown, MD) according to
manufacturer's instructions. qPCR using 16S DNA group-
specific primers for Eubacteria, Lactobacillus/Enterococcus
group (Lact), Bacteroides group (Bact), Clostridium leptum
group (Clept) and E. rectale/C. coccoides group (Erec)
was used to quantify the major intestinal bacteria in the
middle jejunum and the colon [40]. Middle jejunum tissues
were removed, fixed in formalin, embedded in paraffin,
and sectioned into 10 μm pieces. Immunohistochemistry
was used to detect protein expression in the middle je-
junum tissues. Apoptosis was quantified by cleaved caspase
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erating cell nuclear antigen (PCNA) staining [33]. Quanti-
tative RT real-time PCR was used to quantify Lgr5, Olfm4,
Bmi, TNFα, and MCP1 mRNA expression in the middle
jejunum [33]. Cytokine expression in the plasma was mea-
sured using the BDTMCBA (Cytometric Bead Array)
(BD biosciences, San Jose, CA) according to manufac-
turer's instructions [33]. Data were analyzed by one-way
or two-way ANOVA (GraphPad Prism 5, San Diego,
CA), Student’s T-test (Microsoft Office Excel), and cor-
relation analysis (GraphPad Prism 4). Difference were
considered to be statistically significant when P < 0.05.
All animal experiments were carried out in accordance
with an approved Yale University Institutional Animal
Care and Use Committee (IACUC) protocol. Murine
Colon 38 cell lines were provided by Dr. Giuseppe
Pizzorno, Ph.D., Pharm.D (Translational Science, Nevada
Cancer Institute, USA).
Results
Treatment with PHY906, antibiotics, and/or CPT-11 alters
the profile of major intestinal bacteria species
Intestinal bacteria in Colon-38 tumor bearing BDF1 mice
was depleted with streptomycin/neomycin (200 mg/kg,
p.o. bid) for 10 days before (our preliminary result indi-
cated 7-day pre-treatment was not sufficient to deplete in-
testinal bacteria, data not shown) treatment with PHY906
(500 mg, p.o. bid days 0–3) and/or CPT-11 (360 mg/kg,
I.P. day 0). On day 4, qPCR was used to quantify the levels
of major intestinal bacteria in the middle jejunum and in
the colon, using 16S DNA group-specific primers for Eu-
bacteria, Lactobacillus/Enterococcus group (Lact), Bacter-
oides group (Bact), Clostridium leptum group (Clept) and
E. rectale/C. coccoides group (Erec). As seen in Figure 1,
PHY906 treatment significantly decreased levels of Bact
(P = 0.012) and Erec (P = 0.03) (Figure 1A, C, F) but
caused a slight increase in Lact (Figure 1A, B). PHY906
treatment increased levels of Clept but not Lact, Bact,
or Erec in the colon, and it had no effect on Clept levels
in the middle jejunum (Figure 1A, I). CPT-11 treatment
significantly reduced levels of Bact (P = 0.014) and Erec
(P = 0.04) (Figure 1A, H, J) but not Lact or Clept in the
middle jejunum. In the colon, CPT-11 increased the
density of Lact (P = 0.03) (Figure 1A, G). Administration
of PHY906 following CPT-11 treatment significantly in-
creased levels of Clept (P = 0.04) and Erec (P = 0.03)
(Figure 1A, I, J) but not Lact and Bact in the colon. In
middle jejunum, PHY906 + CPT-11 treatment only in-
creased the density of Erec (P = 0.03) (Figure 1A, F).
In the colon, antibiotic treatment depleted the density
of Bact, Clept, and Erec by more than 99% but did not
affect that of Lact (Figure 1A, G-J). In the middle je-
junum, antibiotics reduced levels of Lact, Bact, and
Clept by about 95% and decreased Erec by nearly 80%(Figure 1A-F). After antibiotic treatment, both PHY906
and CPT-11 increased the density of Erec (P = 0.02 and
0.04, respectively) (Figure 1A, J) but not Lact, Bact, or
Clept in the colon; antibiotic + drug treatment also had
no effect on the levels of tested bacteria in the middle je-
junum. It is interesting to note that treatment with CPT-
11, antibiotic, and PHY906 caused a significant increase
in the density of Lact (P = 0.004) (Figure 1A, B) in the
middle jejunum but not the colon. The level of Lact in
CPT11/PHY906/antibiotic-treated mice was nearly 10-fold
higher (P = 0.004) than that observed in the control group
in antibiotic treatment conditions (Figure 1A, B).
Taken together, these studies show that PHY906 and
CPT-11 with or without antibiotic treatment have variable
effects on bacterial profiles in different regions of the in-
testine. Moreover, the interaction between PHY906 and
CPT-11 could change bacterial profiles in the different
segments of intestine.
The effect of antibiotic treatment on the anti-tumor
activities of CPT-11 and CPT-11/PHY906
As it has been shown previously, treatment with PHY906
alone did not affect Colon-38 tumor growth. However,
PHY906 was able to significantly enhance the antitumor
activity of CPT-11 against Colon-38 cells (P < 0.0083)
(Figure 2A). Treatment with antibiotics alone did not
alter Colon-38 tumor growth (Figure 2A). Furthermore,
antibiotic treatment did not affect the antitumor activity
of either PHY906 or CPT-11 (Figure 2A). Most import-
antly, antibiotic treatment had no effect on the ability of
PHY906 to significantly enhance the antitumor activity
of CPT-11 against Colon-38 tumor growth (P < 0.0001).
Cleaved caspase-3 staining indicated that PHY906 in-
creased the level of apoptosis in Colon-38 tumors in-
duced by CPT-11 with (P = 0.014) or without (P = 0.002)
antibiotic treatment (Figure 2B, C).
PHY906 reduced GI damage caused by CPT-11 regardless
of antibiotic treatment
PHY906 treatment did little to reverse the body weight
loss caused by CPT-11 by day 2 but promoted a significant
recovery in body weight by day 4 (Figure 3A), a result con-
sistent with our previous findings [33]. Antibiotic treat-
ment partially mitigated the body weight loss triggered by
CPT-11 between day 2 and day 4 (P = 0.051) (Figure 3A).
PHY906 further protected against CPT-11-triggered body
weight loss regardless of antibiotic treatment (Figure 3A).
There was no difference in animal body weight between
the CPT-11/PHY906 group and the CPT-11/PHY906/
antibiotic group on day 4 (Figure 3A); PHY906 alone
could significantly protect against body weight loss follow-
ing CPT-11 treatment on day 4 (Figure 3A). In conclusion,
PHY906 was able to enhance the antitumor activity
of CPT11 and protect against CPT11-triggered body
Figure 1 Effect of antibiotics, PHY906, CPT-11 and PHY906/CPT-11(9/c) on intestinal bacteria densities in murine Colon-38 tumor-bearing
BDF1 micex. (A) Quantitative PCR heat maps for Lactobacillus/Enterococcus (Lact), Bacteroides (Bact), Clostridium leptum (Clept) and E. rectale/C.
coccoides (Erec). The abundance of bacteria is categorized from high (red) to low (green) as indicated by the bar on the right side of the table. The top
of the bar (100%) indicates the highest density of each bacterial group at each row of the table. (B-J) Quantitative PCR results for Lact, Bact, Clept and
Erec in the middle jejunum (MJ) and colon. Each spot represents a mean of two or three different quantitative real-time PCR experiments (triplicate
samples of each; 5 animals in each treatment group). Student's t-test was used to determine whether differences between treatment groups were
significant. Details of experimental procedures are given in Methods.
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profiles.
Consistent with our previous report [33], mice treated
with CPT-11/PHY906 displayed improved histology in the
middle jejunum, especially in the crypt area, as compared
to mice treated with CPT-11 alone (Figure 3B). PCNA
staining also indicated that the majority of GI crypt cells
in mice treated with CPT-11/PHY906 were actively prolif-
erating (Figure 3C). Antibiotic treatment was able to
protect some crypts from damage caused by CPT-11
but was not nearly as effective as PHY906 treatment
alone (Figure 3B). PCNA staining showed only some
crypt cells actively proliferating in mice treated with an-
tibiotics plus CPT-11 (Figure 3C). PHY906 plus antibiotic
treatment yielded the most pronounced improvement in
the histology of the middle jejunum from damage causedby CPT-11 (Figure 3B). However, RT-qPCR results indi-
cated that antibiotic treatment could affect two important
intestinal progenitor/stem cell markers: Lgr5 and Olfm4
mRNA expression. Antibiotic treatment alone strongly
inhibited Lgr5 mRNA expression (P = 0.001) to a level
similar to that in CPT-11-treated mice (Figure 3D).
However, antibiotic treatment did not affect PHY906’s
induction of Lgr5 mRNA expression following CPT-11
treatment (P < 0.0001) (Figure 3D). Furthermore, al-
though antibiotic treatment did not significantly inhibit
Olfm4 or Bmi mRNA expression (Figure 3E, F), antibiotic
treatment inhibited PHY906’s induction of Olfm4 mRNA
expression following CPT-11 treatment (Figure 3E). These
results suggest that antibiotic treatment or the profile of
intestinal bacteria may in some manner affect the behavior
of intestinal progenitor/stem cells.
Figure 2 Effect of antibiotic treatment on the anti-tumor activity and GI toxicity of PHY906, CPT-11 and PHY906/CPT-11(9/c) in murine
Colon-38 tumor-bearing BDF1 mice. (A) Effect of PHY906 and/or CPT-11 on the growth of Colon 38 tumor cells in BDF1 mice with or without
(w/o) antibiotic treatment. Each spot represents an individual tumor’s size relative to that at initial treatment. One way ANOVA was used to determine
the significance of the differences between curves (B) Immunohistochemistry staining for cleaved caspase-3 in Colon-38 tumor sections under different
treatment conditions as indicated on the graph. Photographs in the figure were taken at 200× magnification. (C) Quantitation of cleaved caspase-3
staining. Cleaved caspase-3 stained cell per each view of Colon-38 tumor sections following different treatment conditions as indicated on the graph.
Each spot represents the mean number of heavily stained cells from 4 to 5 views of each tumor section. Student's t-test was used to determine
whether differences between treatment groups were significant. Details of the experimental procedures are given in Methods.
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toxicity is not affected by antibiotic treatment
As stated previously [33], PHY906 treatment inhibited
several inflammatory processes triggered by CPT-11 in
the middle jejunum, including neutrophil infiltration of
the intestine (Figure 4A) and stimulation of TNF-α andMCP1 mRNA expression (Figure 4B and C). In the plasma,
PHY906 reduced expression of pro-inflammatory cytokines
induced by CPT-11 such as MCP1, G-CSF, and IL6
(Figure 4D-F). Antibiotic treatment also exhibited sub-
stantial anti-inflammatory activity in CPT-11-treated
animals. It should be noted that 10-day pre-treatment
Figure 3 Effect of PHY906 on CPT-11-induced body weight loss and damage of the middle jejunum in murine Colon-38 tumor bearing
BDF1 mice with or without (w/o) antibiotic treatment on day 4. (A) Effect of PHY906 in protecting against weight loss induced by CPT-11
with or without (w/o) antibiotic treatment. Error bars indicate standard deviations; N = 5. (B) Hematoxylin and eosin staining for visualizing the
formalin fixed sections of the middle jejunum four days after treatments commenced. Photographs were taken at 200x magnification. (C) Effect
of PHY906 on the expression of Proliferating Cell Nuclear Antigen (PCNA) following CPT-11 treatment with or without antibiotic treatment. (D-F) qPCR
for the mRNA expression of the proposed intestinal stem cell markers Lgr5, Olfm4 and Bmi1 in the middle jejunum under different treatment conditions.
β-actin was used as an internal control. Each spot represents the mean of two or three different experiments (triplicate samples of each; N = 5). Student's
t-test was used to determine whether differences between treatment groups were significant. Details of experimental procedures are given in Methods.
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intestinal inflammation as reflected by a reduction in
TNF-α (P = 0.003) and MCP1 (P = 0.01) mRNA (Figure 4B
and C). However, antibiotic treatment did not affect basal
levels of pro-inflammatory cytokines in the plasma.
Discussion
The Chinese herbal medicine Huang-Qin Tang has a
nearly 2000-year history of use for treatment of GI side
effects such as diarrhea, nausea, vomiting, and abdominal
cramps. However, the direct effect of Huang-Qin Tang on
intestinal bacteria levels has never been formally investi-
gated. Herein, we investigated the ability of PHY906, a
standardized cGMP “Huang-Qin Tang” equivalent, to alter
bacterial profiles differently in different segments of intes-
tine. Our in vivo studies have shown that PHY906 does
not act as a broad-spectrum antibiotic against the bacteria
that were tested in our studies. For example, PHY906treatment only inhibited Bact and Erec while antibiotic
treatment decreased all kinds of tested bacteria in the
middle jejunum. Thus, the underlying mechanism of
Huang-Qin Tang for the treatment of diarrhea is com-
pletely different from that of anti-diarrheal antibiotics.
However, one caveat is that PHY906 might still have
antibiotic activity against certain bacteria that were not
tested in the present study. Indeed, several studies have re-
ported that individual herbs of PHY906 possess antibiotic
activity. Different Chemicals of Paeonia lactiflora were
found to have different activities against Bact [41]. It was
found that human intestinal bacteria could transform
flavonoids of Scutellaria baicalensis into aglycone-
flavonoids, baicalein, oroxylin A, wogonin and norwo-
gonin, each of which has different potencies against dif-
ferent types of intestinal bacteria [42]. Glycyrrhizol A and
6,8-diisoprenyl-5,7,4'-trihydroxyisoflavone (5) isolated
form Glycyrrhiza uralensis were shown to exhibit potent
Figure 4 Effect of PHY906 on CPT-11-induced inflammation in murine Colon-38 tumor-bearing BDF1 mice with or without (w/o)
antibiotic treatment on day 4. (A) Neutrophil infiltration in the middle jejunum section after different treatments. Photographs were
taken at 200x magnification. (B and C) qPCR for TNFα and MCP-1 in the middle jejunum after treatment. β-actin was used as an internal
control. Each spot represents the mean from two or three different experiments (triplicate samples of each; N = 5). (D-F) Detection of TNF-α,
G-CSF and IL6 protein in the plasma after different treatments. (Each spot represents the mean from triplicate samples of each plasma sample;
N = 5). Student's t-test was used to determine whether differences between treatment groups were significant. Details of experimental procedures are
given in Methods.
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Crude ethanol extracts of Ziziphus jujuba fruits were also
reported to exhibit antibacterial activity [44]. Future in-
vestigations, such as a comparison of the impacts of dif-
ferent herbal combinations of PHY906 on intestinalbacterial profiles, could help us to address which herb(s)
or chemical(s) are responsible for which of PHY906’s
antibiotic activities.
Previous studies have shown that treatment of PHY906
with E. coli β-glucuronidase alters the mixture’s bioactivities.
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hibit stronger Wnt3a potentiation activity and anti-TNFα
activity but weaker anti-iNOS activity in vitro [33]. Thus,
using antibiotics to deplete intestine bacteria, which have
high β-glucuronidase activity, would be expected to have
an antagonistic effect on PHY906’s biological activity. In
addition, antibiotic treatment should also lead to reduced
SN38 formation and damage of intestinal tissues. Strepto-
mycin/neomycin treatment depleted over 90% of the
major bacteria species in the gut. This finding is consist-
ent with other reports in the literature [24,45]. We
observed that antibiotic treatment partially protected in-
testinal tissue from CPT-11 toxicity without enhancing
CPT-11’s antitumor activity. In contrast, PHY906 was able
to reduce the extent of GI damage while enhancing the
antitumor activity of CPT-11. Thus, our studies suggest
that PHY906 is able to maintain its biological activity in
the presence of a wide range of intestinal bacteria and
their respective β-glucuronidases. Perhaps human β-
glucuronidase and UDP-glucuronosyltransferase (UGT),
both of which are expressed in intestinal tissues, may
impact PHY906 metabolism. In our phase I/ll clinical
trial for treatment of mCRC patients, most plasma flavo-
noids from the orally administrated PHY906 were found
to be glucuronidated, although some were sulfonated or
methylated [46]. Our preliminary studies suggest that both
human glucuronidase and UGT(s) play key roles in the
metabolism of flavonoids in PHY906.
Treatment with either PHY906 or antibiotics may be
able to reduce CPT-11-induced inflammation, including
neutrophil infiltration of intestine, MCP1 and TNF-α
mRNA expression in the intestine, and increased ex-
pression of pro-inflammatory cytokines G-CSF and
MCP1 proteins in the plasma. However, it appears that
PHY906 and antibiotics have different mechanism of
action. It is known that intestinal bacteria are normally
localized to the loose mucus and cannot penetrate the
inner mucus layer [47-49]. However, damage to the mucus
layer by CPT-11 allows intestinal bacteria to come in con-
tact with epithelial cells or enter the blood stream, thus
triggering the inflammatory process. Antibiotic treatment
significantly reduces the level of intestinal bacteria and re-
duces the likelihood of bacteria-induced inflammation fol-
lowing CPT-11 treatment. This could also explain why
antibiotic treatment alone reduced the basal level of MCP1
and TNF-α mRNA expression. In contrast, PHY906 accel-
erates the repopulation of epithelial cells, which restore the
mucus layer and thus prevent bacterial penetration.
PHY906 also suppresses inflammation by targeting several
key signaling pathways, including NF-κB, iNOS, and
COX2. For these reasons, the combination of antibiotics
with PHY906 appears to more effectively suppress CPT-
11-triggered inflammation and preserve the intestinal
histological structure than either component alone.However, while antibiotic treatment did not affect
PHY906’s induction of Lgr5 expression, it did suppress
expression of intestinal progenitor/stem cell markers
and inhibit PHY906’s ability to increase Olfm4 and Bmi
levels following CPT-11 treatment. Lgr5 [50,51], Olfm4
[52], and Bmi [53] all play important roles in maintain-
ing the growth of intestinal progenitor/stem cells in the
crypts of different segments of the intestine; intestinal
bacteria can thus modulate intestinal stem cell prolifera-
tion to maintain gut homeostasis via the JAK–STAT and
JNK pathways as demonstrated in Drosophila [54].
Therefore, the combination of PHY906 and antibiotics
may not be the optimal approach to protect intestinal
tissues from damage caused by CPT-11 or other toxic
agents.
Inflammatory bowel diseases (IBD), including ulcera-
tive colitis and Crohn’s disease, are caused by an innate
immune response to luminal microflora in individuals
with a certain genetic disposition. A recent finding indi-
cated that the density of Clept is significantly reduced
in the fecal microbiota of patients with Crohn’s disease
and ulcerative colitis [39]. Our results showed that
PHY906 alone can increase the density of Clept in co-
lonic tissue. PHY906 is also able to maintain Clept and
Erec levels in the colon following CPT-11 treatment.
Therefore, PHY906 may have potential benefit in treat-
ing IBD by restoring the density of Clept in the colon.
In addition, PHY906 inhibits NF-κB, COX2, and iNOS,
all of which play key roles in IBD [55-57]. Thus, the po-
tential use of PHY906 in treating IBD is worthy of fur-
ther investigation.Conclusions
Our studies have shown that the depletion of intestinal
bacteria by antibiotics does not impact the ability of
PHY906 to enhance CPT-11’s antitumor activity and to
protect against CPT-11-induced intestinal toxicity. Pa-
tients with a range of intestinal bacterial profiles may
thus benefit from the use of PHY906 as a modulator of
CPT-11-based treatment.Abbreviations
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